Eledon Pharmaceuticals (ELDN) to Release Quarterly Earnings on Thursday

Eledon Pharmaceuticals (NASDAQ:ELDN) is expected to post its Q4 2025 results before the market opens on Thursday, March 19th. Analysts expect Eledon Pharmaceuticals to post earnings of ($0.20) per share for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, March 26, 2026 at 4:00 PM ET.

Eledon Pharmaceuticals Stock Down 4.8%

Eledon Pharmaceuticals stock opened at $2.76 on Thursday. The company has a 50 day moving average of $2.18 and a 200-day moving average of $2.33. Eledon Pharmaceuticals has a twelve month low of $1.35 and a twelve month high of $4.60. The stock has a market capitalization of $165.41 million, a PE ratio of -2.60 and a beta of 0.84.

Hedge Funds Weigh In On Eledon Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. Virtu Financial LLC acquired a new stake in shares of Eledon Pharmaceuticals in the fourth quarter valued at about $39,000. XTX Topco Ltd boosted its position in Eledon Pharmaceuticals by 867.1% during the fourth quarter. XTX Topco Ltd now owns 124,247 shares of the company’s stock valued at $188,000 after purchasing an additional 111,399 shares during the last quarter. Zimmer Partners LP grew its stake in Eledon Pharmaceuticals by 30.6% in the fourth quarter. Zimmer Partners LP now owns 2,384,228 shares of the company’s stock valued at $3,600,000 after purchasing an additional 559,228 shares in the last quarter. Sphera Funds Management LTD. grew its stake in Eledon Pharmaceuticals by 97.4% in the fourth quarter. Sphera Funds Management LTD. now owns 2,132,131 shares of the company’s stock valued at $3,220,000 after purchasing an additional 1,051,898 shares in the last quarter. Finally, Quadrature Capital Ltd increased its position in shares of Eledon Pharmaceuticals by 291.2% during the 4th quarter. Quadrature Capital Ltd now owns 106,014 shares of the company’s stock worth $160,000 after purchasing an additional 78,914 shares during the last quarter. Institutional investors own 56.77% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently weighed in on ELDN shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eledon Pharmaceuticals in a research note on Monday, December 29th. Guggenheim cut their price target on Eledon Pharmaceuticals from $9.00 to $8.00 and set a “buy” rating on the stock in a report on Tuesday, November 18th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $9.67.

About Eledon Pharmaceuticals

Eledon Pharmaceuticals, Inc (NASDAQ:ELDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of therapies for diseases characterized by smooth muscle dysfunction. The company leverages a proprietary ion-channel modulation platform to identify and optimize small-molecule compounds that can either restore or inhibit smooth muscle activity, with the goal of addressing gastrointestinal, hepatic and cardiovascular disorders.

Eledon’s pipeline comprises several preclinical and early-phase clinical programs targeting high-unmet-need indications.